Deproteinized Calfblood Extract
- Generic Name
- Deproteinized Calfblood Extract
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
⑴用于脑卒中、脑外伤、周围血管病及腿部溃疡。
⑵亦可用于皮移植术、烧伤、烫伤、糜烂、创伤、褥疮的伤口愈合；放射所引起的皮肤、黏膜损伤。
⑶各种病因引起的角膜溃疡，角膜损伤，酸或碱引起的角膜灼伤，大疱性角膜炎，神经麻痹性角膜炎，角膜和结膜变性等。
- Associated Conditions
- -
- Associated Therapies
- -
Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB
- First Posted Date
- 2018-03-19
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 366
- Registration Number
- NCT03469349
- Locations
- 🇰🇿
"National scientific centre of oncology and transplantology", Astana, Kazakhstan
🇷🇺SBHI of Ryazan region Regional clinical cardiological dispensary, vessel surgery department/ FSBI of Ryazan Region "Ryazan State Medical Univesity n.a. I.P. Pavlov" of MoH of Russia, Ryazan, Russian Federation
🇬🇪Center of Vascular and Heart Disease, Tbilisi, Georgia
Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)
Phase 3
Completed
- Conditions
- Post-Stroke Cognitive Impairment (PSCI)
- Interventions
- Drug: ActoveginDrug: Placebo
- First Posted Date
- 2012-04-23
- Last Posted Date
- 2016-02-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 503
- Registration Number
- NCT01582854
- Locations
- 🇷🇺
Nycomed Investigational Site, Tomsk, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath